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INTRODUCTION
In the previous papers in this series (Bradburn et al, 2003a,b;
Clark et al, 2003), we discussed methods for analysing survival
time data, both univariate and multivariate. We have dealt with
only a portion of the methods available for analysing survival time
data, and in many cases, useful alternatives to (or extensions of)
these methods exist. We have also left unanswered other questions
regarding the design and analysis of studies that measure survival
time and, in particular, dealing with situations where some
standard modelling assumptions do not hold. We conclude this
series by tackling these issues. These ideas are described in a
question and answer format, and introductory references are
provided for the reader to investigate further.
IN A SURVIVAL ANALYSIS, CONTINUOUS
VARIABLES ARE SOMETIMES CATEGORISED.
SHOULD WE DO THIS (AND IF SO, HOW)?
In medical research, it is common to see continuous measures
grouped into categories to simplify a covariate’s relationship with
survival and its interpretation. There is no statistical reason for
grouping and it can lead to as many problems as it seeks to avoid.
The categorisation of a continuous covariate by definition discards
data and can be seen as introducing measurement error. It also
leads to biased estimates and a reduced ability to detect real
relationships (Schmoor and Schumacher, 1997; Altman, 1998).
Nevertheless, there are sometimes good reasons to categorise a
continuous covariate in the analysis of survival (and indeed any)
data. When doing so, it is wise to note the following points:
1. Use cut-points that have been predetermined rather than
testing multiple values. A common choice of boundaries is
fixed centiles such as quartiles. It is preferable though to use
established cut-points that have clinical meaning, and therefore
provide consistent groupings between studies. Examples
include dividing oestrogen receptor level at 10fmol, and age
into 5- or 10-year intervals.
2. Do not choose cut-points based on minimising P-values, as this
method gives biased results (Altman et al, 1994; Altman, 1998).
3. If possible, use more than two categories to reduce the loss of infor-
mation and allow some assessment of the linearity of any trend.
4. Ensure that each group contains an adequate number of
individuals (and events).
Grouping is sometimes used because there are concerns with
mismodelling the relationship when there is a nonlinear relation-
ship between the variable and log hazard. The simplest approach is
to evaluate the effect of adding a quadratic term to the model, but
better approaches to use are smoothing splines (Therneau and
Grambsch, 2000) or fractional polynomials (Royston et al, 1999).
Figure 1 shows the result of modelling a new covariate, (log)
CA125, in the previously used ovarian cancer data, by the method
of smoothing splines (with 11 degrees of freedom). There is
evidence of nonlinearity (P¼0.002) and the plot suggests
that CA125 might be modelled as a cubic effect. It is clear that
modelling the data using a binary or linear variable would be
inappropriate here (see Figure 1). Knorr et al (1992) discussed
these issues in the context of prognostic studies in cancer.
IN OUR CLINICAL TRIAL, WE COLLECTED
MEASUREMENTS AT PREARRANGED VISITS.
CAN WE INCLUDE MULTIPLE MEASUREMENTS
FOR THE SAME COVARIATE IN OUR SURVIVAL
ANALYSIS?
If variables measured after entry into the study are to be included
in the survival model, special methods are required. Such methods
are called time-dependent (or updated) covariate methods, as the
variables they incorporate may change value over time. For
example, if a longitudinal study seeks to assess the effects of
smoking on cancer, a variable for each patient may be defined,
being equal to 0 (nonsmoker) or 1 (smoker) at any time. If a
nonsmoker begins smoking after entering the study, then this
covariate is updated (from ‘0’ to ‘1’) at the time that smoking
begins. This covariate contributes more information than using
smoking status at time of entry alone. It is important to note that
post-entry measurements cannot be validly incorporated into a
survival model without using these methods.
Recall that for the proportional hazards model, the formula
relating a covariate x1 to the hazard h(t) at time t is
hðtÞ¼h0ðtÞexp½b1 x1 
where h0(t) is the baseline hazard. If repeated measurements of a
covariate x1 are available, the formula changes to
hðtÞ¼h0ðtÞexp½b1 x1ðtÞ  Received 6 December 2002; accepted 30 April 2003
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harder to interpret, an accelerated failure time model here.) The
covariate x1 may be continuous or categorical, and may change
freely or at fixed time intervals. The coefficient b1 represents the
additional relative hazard for each unit increase in x1 at any given
time. This model is different from models with time-dependent
coefficients (Bradburn et al, 2003b), in which the effect of a
covariate changes rather than the value of the covariate itself, that
is, h(t)¼h0(t)exp[b1(t) x1].
The time dependent method can be applied in many standard
statistical software packages. However, the approach described
requires a large amount of data and is therefore rarely seen. One
also has to be confident that the collection process is not itself
dependent on clinical progress, perhaps by using scheduled
assessments. Further details of the method, and some precautions,
are noted in Altman and De Stavola (1994).
MOST SURVIVAL ANALYSIS METHODS ASSUME THE
CENSORING IS NONINFORMATIVE. WHAT IF THE
CENSORING IS INFORMATIVE?
Informative censoring occurs when individuals are lost to follow-
up for reasons that may relate to their (unknown) outcome. For
example, in a randomised trial in which the main outcome is time
to cancer recurrence, a patient who is lost to follow-up may be
more likely to have experienced drug toxicity or ill health and thus
may also be more susceptible to (earlier) relapse. Informative
censoring introduces bias into the standard methods discussed
previously. Unfortunately, it is difficult both to identify informa-
tive censoring and to assess its impact. It is helpful though to know
what proportion of censored individuals were lost to follow-up
before the end of the study (Clark et al, 2002).
A simple, ad hoc approach to the problem is to perform
sensitivity analyses, to assess the impact of assigning different
survival times to those patients whose observed (censored)
survival times may have been affected in this manner. For
example, if a patient suspected to be in ill health exits the study
at 4 weeks, a first analysis may be performed with this patient
censored at 4 weeks and a second where the patient is assumed to
have relapsed at 4 weeks (i.e. a ‘best case – worst case’ scenario).
This approach works best when there are few such patients, but in
that situation, the possible bias will be very small. Another
possibility is to decide a priori that all such patients will be treated
in a particular way. The issue has been of particular concern in
randomised trials of nicotine replacement therapy, in which losses
to follow-up are considerable. In a systematic review of
randomised trials, patients who were lost to follow-up were
regarded as being continuing smokers (Silagy et al, 2002).
More formal approaches have been proposed (e.g. Robins,
1995a,b; Scharfstein et al, 2001). In general, they assume that a
relationship exists (and can be modelled) between censoring times
and baseline covariates and perhaps also post-treatment patient
data. It is difficult to evaluate the assumptions of these complex
methods, and implementation in statistical software is limited.
If follow-up stops because the patient has experienced a
different defined event, the problem may be viewed as a competing
risk scenario (see below), or handled via a mixture model (or ‘cure’
model), where the differing event types are explicitly modelled.
The latter method makes particular sense if the two events are
quite dissimilar, such as patient recovery and patient death.
In practice, if there is little informative censoring, the bias
introduced to standard methods is minimal, and in general using
these along with simply reporting loss to follow-up (perhaps with a
basic sensitivity analysis) will suffice. Good patient follow-up and
avoidance of unnecessary drop-out is by far the best solution, and
when and why drop-out occurs should always be reported (Moher
et al, 2001).
SOME COVARIATE DATA ARE MISSING IN OUR
ANALYSIS. WHAT SHOULD WE DO?
Missing data are a common problem when developing survival
models in cancer. Individuals without complete covariate data are
usually omitted, but the resulting analysis has reduced power and
may be an unrepresentative subset of patients. Often many
covariates have missing data, and the absence of a small
percentage of data points for each variable can lead to a greatly
depleted sample. Unless only a few values are missing, some
investigation of the missing data and methods that accommodate it
should be considered. In the ovarian cancer data set presented
previously, a small number of important factors containing little or
no missing data were used. The database contains several other
factors in which missing data were frequently encountered, and a
more definitive analysis (Clark et al, 2001) was able to incorporate
these factors, while retaining all patients by applying multiple
imputation methods (Van Buuren et al, 1999). Multiple imputation
is a framework in which missing data are imputed or replaced with
a set of plausible values. Several data sets are then constructed,
each being analysed separately, and their results are combined
while allowing for the uncertainty introduced in the imputation.
Other approaches exist (e.g. Lipsitz and Ibrahim, 1998), but
imputation approaches have more software available (Horton and
Lipsitz, 2001). Further details, discussion and references are given
in another analysis of the ovarian data found in Clark and Altman
(2002).
We recommend that authors of research papers are explicit
about the amount of missing data for each variable and indicate
how many patients did not have complete data. Imputation
techniques are powerful tools and are increasingly available in
software, but are not a panacea. Inherent in the method is the
assumption that a model relating data absence to other measured
covariates (and possibly survival too) exists and can be specified.
This has much in common with the situation where informative
censoring is suspected, and similarly, their practical experience is
limited at the present time. Researchers should be aware of the
assumptions, most of which are untestable, and use sensitivity
analysis to assess the robustness of results. Ultimately, these
problems are best avoided by minimising missing data.
HOW SHOULD WE CHOOSE WHICH VARIABLES TO
INCLUDE IN OUR SURVIVAL MODEL?
In some cases, the factors to be included in the model will be
predetermined. In many others, there will be several possible
covariates from which only a handful are to be chosen. This is
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Figure 1 Modelling log CA125 using spline functions: | corresponds to
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are unimportant, but the identification and elimination of these is
not always easy. As a starting point, it is good practice to include
known prognostic factors and any that are specifically required by
the study aims (e.g. the treatment identifier in the analysis of a
clinical trial). It is then the burden of new factors to add significant
additional predictive ability (Simon and Altman, 1994).
If there are a large number of factors of interest and there is
relatively little information about their prognostic influence,
automated selection techniques such as stepwise methods can be
used. There are variations on these that start either with all
covariates (backward elimination) or none (forward selection),
adding or removing covariates according to statistical significance
at some predecided level. A disadvantage of both is that they only
evaluate a small number of the set of possible models. Instead,
each possible model could be fitted, with the best being picked on
the basis of a goodness-of-fit measure such as Mallow’s C (Hosmer
and Lemeshow, 1999). However, this may be time-consuming with
many covariates, multiple testing is problematic, and is seldom
used due to its noninclusion in many software packages.
Unfortunately, all these methods are problematic. The ‘best’
model is derived solely on statistical grounds (and indeed may lack
any clinical meaning), the regression coefficients produced are
biased (too large) and standard errors and P-values are too small,
especially for smaller sample sizes and when few events occur.
Backward elimination is possibly the best of the above methods for
identifying the important variables, and it allows one to examine
the full model, which is the only fit providing accurate standard
errors and P-values (Harrell, 2001). An alternative, the lasso
method (Harrell, 2001) attempts to force some regression
coefficient estimates to be exactly zero, thus achieving variable
selection while shrinking the remaining coefficients toward zero to
reflect the overfitting and overestimation caused by data-based
model selection.
If one cannot completely prespecify a model, it may be best to
apply backward elimination or lasso to a full model of prespecified
covariates of interest, and use bootstrap methods to compare the
stability and predictive accuracy of the full model with that of a
reduced one (see next question for further details).
WE HAVE DEVELOPED A PROGNOSTIC MODEL FOR
OVERALL SURVIVAL. HOW CAN WE MEASURE ITS
PREDICTIVE ABILITY? HOW CAN THE MODEL BE
VALIDATED?
In survival analysis, statistical models are employed to identify or
propose combinations of risk factors that might predict patient
survival. It follows that to be of use, the model must be able to: (1)
make unbiased predictions, that is, give predicted probabilities
that match closely those observed, and (2) distinguish higher and
lower risk patients. These are the two components of predictive
ability, and are called calibration and discrimination, respectively.
Importantly, models rarely perform as well on either basis when
used to predict survival in patients other than those used to derive
the model. A model that closely mirrors the survival patterns of the
present data is said to have internal validity, but to be of wider use
should do so for other groups of patients as well (be externally
valid). Before a model is applied routinely in clinical practice, it
should have been shown to meet both criteria.
Measures of discrimination include the c-index and Nagelk-
erke’s R
2(RN
2) (Harrell, 2001). The c-index, a generalisation of the
area under the receiver operating characteristic (ROC) curve, is the
probability of concordance between observed and predicted
survival based on pairs of individuals, with c¼0.5 for random
predictions and c¼1 for a perfectly discriminating model.
Similarly, RN
2 ¼0 indicates no predictive ability and RN
2 ¼1
indicates perfect predictions. Calibration may be quantified using
an estimate of slope shrinkage (Harrell, 2001). Each quantity may
be evaluated for the data used in the modelling by randomly
splitting the patients into two samples, one to derive the model and
the other to validate it. The proportion of data to include in each
sample is, however, arbitrary and although estimates of predictive
accuracy from this approach are unbiased, they also tend to be
imprecise. Bootstrapping, a method that involves analysing
subsamples from a data set, or ‘leave-one out’ cross-validation
may be more beneficial. For these analyses, an alternative is to
estimate shrinkage factors and apply these to regression coeffi-
cients to counter overoptimism. These techniques allow evaluation
on multiple data sets. Once the internal validity of a model has
been established, it can be tested for its generalisability by applying
the model to other patients, and using the above methods to assess
the adequacy of the predictions.
A good summary of important issues can be found in Justice et al
(1999) and Wyatt and Altman (1995), and more details on the
statistical methods are given in Altman and Royston (2000). In
summary, internal validation is necessary before a model is
proposed, and external validation is highly recommended before it
is to used in clinical practice.
CAN WE PERFORM AN ANALYSIS WHERE THERE
ARE UNMEASURED FACTORS THAT MAY AFFECT
SURVIVAL TIME?
In practice, one cannot be sure that all important prognostic
variables have been measured. In general, omitting variables will
simply reduce the predictive ability of a model, so that patients
with similar measured covariates will exhibit large variability in
their survival. When a strongly prognostic variable is omitted,
however, the model may be biased. In particular, the estimated
treatment effect in a randomised trial may be biased if an
important prognostic variable is not adjusted for, even when that
variable is balanced between the treatment groups (Schmoor and
Schumacher, 1997; Chastang et al, 1988). It is inappropriate to
proceed at all if vital information such as clinical stage in breast
cancer patients is unavailable.
Another form of missing covariate is when some individuals
have a shared exposure that is unmeasured. For example, members
of the same family will have shared dietary and other environ-
mental exposures, so that their outcomes cannot be considered to
be independent. A similar situation arises in cluster randomised
trials and multicentre trials in general (Yamaguchi et al, 2002).
Such data can also be considered as being ‘multilevel’, with
variation both between and within groups. Random effects (or
‘frailty’) models can be used to allow covariate effects to vary
across groups (O’Quigley and Stare, 2002). Such models are widely
used in other contexts, in particular, in meta-analysis. Frailty can
also be considered to apply to individuals, relating to the idea of
unmeasured variables as a possible explanation for observed
heterogeneity of outcome. Use of such models depends on precise
knowledge of the frailty distribution, which is generally not
available (Keiding et al, 1997).
Lack of fit of a Cox model may be better explained by other
modelling approaches (O’Quigley and Stare, 2002), such as the
accelerated failure time model (Keiding et al, 1997).
SEVERAL PAPERS IN OUR RESEARCH AREA HAVE
APPLIED (ARTIFICIAL) NEURAL NETWORKS AND
REGRESSION TREES AS AN ALTERNATIVE TO THE
COX MODEL. WHAT ARE THESE METHODS?
Artificial neural networks
Artificial neural networks (ANNs) are a relatively new method for
assessing the extent to which a series of covariates explain patient
Concepts and methods in survival analysis
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that there are some latent, or ‘hidden’, intermediary variables in
the input (covariate) and output (survival probability) processes.
The most common model is the three-layer model shown in
Figure 2. Under this model, the covariates (input) do not act
directly on the response variable (output), but channel their
influence into a series of latent (hidden) variables. It is the relative
importance of these unobservable variables which determines the
survival. For a more detailed introduction to these methods, see
Cross et al (1995).
This methodology is appealing in that it can incorporate
complex relationships between covariates and survival more easily
than standard approaches such as Cox regression, which may be
too simplistic. However, there have been several major criticisms
of the method: (a) the high chance of overfitting the data, (b) the
lack of easy interpretation of the model and of the impact of
individual covariates, (c) the perceived ‘black box’ methodology
involved, and (d) the difficulty in handling censored survival
times. The last issue arises because it is usually the status of the
individuals (i.e. alive or dead) at a given point (or points) in time
that is taken to be the response. Biganzoli et al (1998) and others
have modelled the hazard functions directly, in a promising
attempt to extend this method. Reviews comparing the examples
where both ANN and regression methods had been used to derive
prognostic models have found that overall ANNs are little better
than classical statistical modelling approaches (Sargent, 2001), and
misuses of ANNs in oncology are common (Schwarzer et al, 2000).
We therefore advise caution in their use, and the involvement of an
experienced statistician.
Classification and regression trees
The classification and regression tree (C&RT) approach is based
on dividing the cohort into groups of similar response patterns,
using covariates (Lausen et al, 1994). The partitioning algorithm
starts with the covariate that best discriminates the survival
outcome between two subgroups. For continuous or multicategory
variables, the method thus needs to determine the threshold that
best dichotomises the variable. This process is repeated for each
subgroup in turn using all the available covariates. The same
covariate may be used more than once, and the process stops
eventually with either no covariate adequately dividing the
subgroups further or when the subgroups have reached a specified
minimum size. Figure 3 shows an unpublished C&RT analysis in a
Dukes’ B colonic cancer study, in which four categorical variables
(perforation, peritoneal involvement, venous and margin) were
assessed for their prognostic value in overall survival. Using a
logrank test at each step, it was found that peritoneal involvement
(levels 1, 2 vs 3, 4) discriminated best between good and bad
survival, and level 1 venous subdivided patients with high levels of
peritoneal involvement. The stopping rule employed was the first
occurrence of either (a) the maximum logrank statistic is not
statistically significant at the 1% level or (b) when any subgroup
contains less than 25 patients. The latter condition ceased the
partitioning algorithm in the example, yielding the three groups of
patients described in Figure 3.
The major advantage of C&RT is its ease of interpretability – it
reflects how many decisions are made. It also relies on fewer
distributional assumptions (Schmoor et al, 1993) and is particu-
larly useful in situations where there are interactions. The
disadvantages of C&RT lie in having to decide what threshold to
use for continuous covariates, and to correct for multiple testing
and overfitting. The automated covariate selection is similar to
forward stepwise methods in regression, and hence shares their
problems (see the choice of covariate section). Finally, as C&RT
seeks to classify patients into groups, it offers little in the way of
estimated effect of risk factors. Nevertheless, C&RT is a useful
complement to other methods, in particular as an exploratory tool
that can inform future research.
CAN WE ANALYSE DIFFERENT TYPES OF EVENTS OR
REPEATED EVENTS?
Traditional survival analysis methods (including all those dis-
cussed so far) assume that only one type of event of interest
occurs, and at most once. More advanced methods exist to allow
the investigation of several types of events (e.g. cancer death,
vascular death, other), or an event that may occur repeatedly (e.g.
cancer recurrence). We will describe methods for each in turn.
Where the survival duration is ended by the first of several
events, it is referred to as competing risks analyses. Analysing the
time to each event separately can be misleading, and in this context
the Kaplan–Meier method, in particular, tends to overestimate the
proportion of subjects experiencing each event. The cumulative
Output
layer
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layer
Input
layer
Figure 2 An example of an ANN.
(95% CI) 
N Deaths
(I)  Peritoneal 1 or 2  87.1 (80.2, 91.7)  158 21
(II)  Peritoneal 3 or 4 and venous 1 73.7 (58.8, 83.9)  54 13
(III) Peritoneal 3 or 4 and venous 2 or 3  45.7 (31.0, 59.3)   57 29
N=269
Peritoneal involvement?
N=158
(I) 
N=57 
(III)
Level 1 or 2
N=111 
Venous?
Level 3 or 4
N=54 
(II)
Level 1 Level 2 or 3
5-year survival 
Figure 3 A CART for Dukes’ B colonic cancer study.
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time is the sum of the event-specific probabilities, may be used to
address this. Univariate tests and statistical models also exist, and
an overview of several of the methods proposed can be found in
Tai et al (2001). Models are generally implemented by entering
each patient several times – one per event type – and for each
patient, the time to any event is censored on the time at which the
patient experienced another event.
Where multiple events of the same type occur, it is common
practice to use the first event only, but this ignores information.
Three approaches to use this extra information are demonstrated
using artificial patient data in Table 1. In a conditional model,
follow-up time is broken up into segments defined by events, with
each patient being at risk for an ith event once the (i 1)th has
occurred. Patient 1 in Table 1 is therefore assumed not to be at risk
of a second event until the first has occurred, and so is at risk of
experiencing this from time 8 until time 12. This model comes in
two types: using either the time since the beginning of the study
(type A) or the time since the previous event (type B). The
marginal model, on the other hand, considers each event to be a
separate process and, by definition, the time for each event starts
at the beginning of follow-up for each patient. Here, all patients are
considered to be at risk for all events, regardless of how many
events they have previously had, and so patient 2, for example, was
considered at risk of events 3 and 4 despite being lost to follow-up
at the second. A third approach, called the independent increment
model, is closest in spirit to a conditional model but takes no
account of the number of previous events experienced by a patient,
and for this reason the conditional and marginal models are often
preferable. For each model, the data should be entered in the form
of one patient record per event number as illustrated in Table 1.
All of the above models are usually applied within a Cox model
framework, although accelerated failure time methods may equally
be used. These models are fitted using the same basis as standard
approaches, with two exceptions: (1) a cluster effect is used to
adjust the standard errors because patients are repeated in the
study, and (2) the analysis is stratified – with the exception of the
independent increment method – with the event type (for
competing risks) or number (for recurrent events) defining the
strata. Interaction effects between covariates and strata may be
used to assess whether covariate effects vary across competing
outcomes or event number. For example, Kay (1986) presents an
example of a treatment that reduces the risk of death from one
cause, but increases the risk of death from another.
More thorough reviews of the above (and other related) methods
can be found in Hosmer and Lemeshow (1999), and Therneau and
Grambsch (2000). These modelling procedures are generally only a
little more difficult than for single-event data, and software is
widely available. As with any statistical model though, it is still
important to assess its adequacy and fit. In each case, the choice of
the best method of analysis will depend on the disease in question
and the goals of the analysis. However, the aims such as those
described here can often be highly relevant, and where this is the
case these methods should be strongly considered.
SUMMARY
Most analyses of survival data use primarily Kaplan–Meier plots,
logrank tests and Cox models. We have described the rationale and
interpretation of each method in previous papers of this series, but
here we have sought to highlight some of their limitations. We
have also suggested alternative methods that can be applied when
either the data or a given model is deficient, or when more difficult
or specific problems are to be addressed. For example, analysis of
recurrent events can make an important contribution to the
understanding of the survival process, and so investigating repeat
cancer relapses may be more informative than concentrating only
on the time until the first. More fundamentally, missing data are a
common issue in data collection that in some cases can seriously
flaw a proposed analysis. Such considerations may be highly
relevant to the analysis of a data set, but are rarely mentioned in
the analysis of survival data. One possible reason for this is a
perceived lack of computer software, but many of the approaches
discussed here are currently incorporated into existing commercial
statistical packages (e.g. SAS, S-Plus, Stata) and freeware (e.g. R).
On the other hand, the desire may be to ‘keep things simple for the
readership’. This view is reasonable, but is valid only where a
simple analysis adequately represents the survival experience of
patients in the study. Ensuring the analyses are appropriate is
therefore crucial. More advanced survival methods can derive
more information from the collected data; their use may
admittedly convey a less straightforward message, but at the same
time could allow a better understanding of the survival process.
The aim of this series has been to aid awareness, understanding
and interpretation of the many and varied methods that constitute
the analysis of survival data. It is paramount that analyses are
performed in the knowledge of the assumptions that are made
therein, and the more complex methods, in particular, are best
applied by a statistician.
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Table 1 Data layout under four recurrent event models with patient 1
having three events (at times 8, 12 and 26) and patient 2 having two events
(at times 10, 18)
Model Patient i.d. Time interval Event
a Stratum
b
Conditional A 1 (0,8] 1 1
1 (8,12] 1 2
1 (12,26] 1 3
1 (26,31] 0 4
2 (0,10] 1 1
2 (10,18] 1 2
Conditional B
c 1 (0,8] 1 1
1 (0,4] 1 2
1 (0,14] 1 3
1 (0,5] 0 4
2 (0,10] 1 1
2 (0,8] 1 2
Marginal model 1 (0,8] 1 1
1 (0,12] 1 2
1 (0,26] 1 3
1 (0,31] 0 4
2 (0,10] 1 1
2 (0,18] 1 2
2 (0,18] 0 3
2 (0,18] 0 4
Independent increment 1 (0,8] 1 1
1 (8,12] 1 1
1 (12,26] 1 1
1 (26,31] 0 1
2 (0,10] 1 1
2 (10,18] 1 1
a1¼had event of interest, 0¼censored.
bRelates to the number of events and is
used in the fitting of the model as the strata variable.
cGap time model.
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